Shots :
- Followed by the CHMP’s positive opinion in Nov 2023 for Crohn’s disease, psoriasis and psoriatic arthritis, the EC has approved Uzpruvo across the EU and Iceland, Liechtenstein, and Norway
- The approval was based on the analytical & clinical results, data from the study (AVT04-GL-301) comparing the safety and efficacy of AVT04 vs Stelara for treating chronic plaque-type psoriasis demonstrating its similarity as well as results from the (AVT04-GL-101) study showing similar PK characteristics
- Additionally, Alvotech holds rights to develop and manufacture Uzpruvo while STADA is responsible for the commercialization in the EU as per the agreement signed in 2019
Ref: STADA and Alvotech | Image: STADA and Alvotech | Press Release
Related News:- Accord BioPharma Reports US FDA’s Acceptance of BLA for DMB-3115 (Biosimilar, Stelara)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
